EVOKE PHARMA INC's ticker is and the CUSIP is 30049G203. A total of 13 filers reported holding EVOKE PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,994 | -13.2% | 5,793 | +3.8% | 0.00% | – |
| Q2 2023 | $9,207 | +114987.5% | 5,580 | +40.0% | 0.00% | – |
| Q1 2023 | $8 | +300.0% | 3,985 | +367.2% | 0.00% | – |
| Q4 2022 | $2 | -100.0% | 853 | -62.1% | 0.00% | – |
| Q3 2022 | $4,000 | -50.0% | 2,248 | -6.5% | 0.00% | – |
| Q2 2022 | $8,000 | – | 2,403 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 3,985 | $8 | 0.00% |
| Concord Wealth Partners | 114 | $217 | 0.00% |
| Renaissance Technologies | 11,178 | $21 | 0.00% |
| ROYAL BANK OF CANADA | 28 | $0 | 0.00% |
| VANGUARD GROUP INC | 29,851 | $56,717 | 0.00% |
| UBS Group AG | 1,107 | $2,103 | 0.00% |
| NewEdge Advisors, LLC | 208 | $395 | 0.00% |
| WELLS FARGO & COMPANY/MN | 16 | $30 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 20,894 | $39,698 | 0.00% |